Erytech Pharma S.A.

Erytech Pharma S.A. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Erytech Pharma S.A. is not a good value stock. Erytech Pharma S.A. is not a good growth stock. Erytech Pharma S.A. is not very popular among insiders. Erytech Pharma S.A. is a good stock to invest in, but there are better stocks to choose.
Log in to see more information.
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. It engages in dev...
ERYP Fundamental Data by TradingView

News

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023

Globe Newswire ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholders Meeting held on June 23, 2023 All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in ...\n more…

ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit
ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit

Globe Newswire ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP) announces the filing of a new lawsuit by Akkadian Partners. Despite the rejection by ...\n more…

Erytech's Battle With Activist Investor Echoes As Pherecydes Pharma Merger Vote Comes Closer
Erytech's Battle With Activist Investor Echoes As Pherecydes Pharma Merger Vote Comes Closer

Benzinga In February, Erytech Pharma SA (NASDAQ: ERYP) announced its proposed combi\n more…

Erytech Pharma SA (ERYP) Q1 2023 Earnings Call Transcript
Erytech Pharma SA (ERYP) Q1 2023 Earnings Call Transcript

SeekingAlpha Erytech Pharma SA (NASDAQ: ERYP) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Gil Beyen - CEO Thibaut du Fayet - CEO, Pherecydes Pharma Didier Hoch - Chairman, Pherecydes Pharma Conference Call Participants Jacob Mekhael - Kempen & Co.\n more…

Erytech Pharma reports Q1 results
Erytech Pharma reports Q1 results

SeekingAlpha.com: All News Erytech Pharma press release (ERYP): Q1 Cash and cash equivalents of €30.5 million ($33.7 million) at the end of March 2023.At the current stage of transition activities in view of...\n more…